CN104080474B - C1-抑制剂在治疗中枢神经系统继发性水肿中的应用 - Google Patents

C1-抑制剂在治疗中枢神经系统继发性水肿中的应用 Download PDF

Info

Publication number
CN104080474B
CN104080474B CN201280063159.7A CN201280063159A CN104080474B CN 104080474 B CN104080474 B CN 104080474B CN 201280063159 A CN201280063159 A CN 201280063159A CN 104080474 B CN104080474 B CN 104080474B
Authority
CN
China
Prior art keywords
edema
purposes
brain
secondary cases
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280063159.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104080474A (zh
Inventor
C·克莱因施尼茨
M·诺尔特
G·施托尔
G·迪克奈特
S·舒尔特
B·尼斯万特
I·普拉格斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of CN104080474A publication Critical patent/CN104080474A/zh
Application granted granted Critical
Publication of CN104080474B publication Critical patent/CN104080474B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280063159.7A 2011-12-22 2012-12-21 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用 Active CN104080474B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11195254.5 2011-12-22
EP11195254 2011-12-22
US201261587371P 2012-01-17 2012-01-17
US61/587,371 2012-01-17
PCT/EP2012/076691 WO2013093027A1 (en) 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system

Publications (2)

Publication Number Publication Date
CN104080474A CN104080474A (zh) 2014-10-01
CN104080474B true CN104080474B (zh) 2016-04-27

Family

ID=48667767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280063159.7A Active CN104080474B (zh) 2011-12-22 2012-12-21 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用

Country Status (10)

Country Link
US (1) US9452203B2 (enExample)
EP (1) EP2793935B1 (enExample)
JP (1) JP6127063B2 (enExample)
KR (1) KR102022231B1 (enExample)
CN (1) CN104080474B (enExample)
AU (1) AU2012318275B2 (enExample)
CA (1) CA2858984C (enExample)
DK (1) DK2793935T3 (enExample)
ES (1) ES2587863T3 (enExample)
WO (1) WO2013093027A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
CN110818798A (zh) 2012-10-25 2020-02-21 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
SMT201700415T1 (it) 2013-03-15 2017-11-15 Shire Viropharma Inc Composizioni di c1-inh per l’uso nella prevenzione e nel trattamento dell’angioedema ereditario (hae)
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (en) * 2014-11-21 2016-05-26 Kurt Baekgaard Osther Recombinant c1 esterase inhibitor and use thereof
HUE061076T2 (hu) 2015-04-06 2023-05-28 Bioverativ Usa Inc Humanizált anti-C1s ellenanyagok alkalmazási eljárások
BR112018010160A8 (pt) * 2015-11-19 2019-02-26 Shire Human Genetic Therapies inibidor da c1 esterase humana recombinante e usos do mesmo
DK3525583T3 (da) 2016-10-12 2025-10-27 Bioverativ Usa Inc Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365478A (zh) * 2005-12-21 2009-02-11 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
JP3941174B2 (ja) 1996-08-26 2007-07-04 富士ゼロックス株式会社 複合材料及びその製造方法
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
PL1965831T3 (pl) 2005-12-21 2011-12-30 Pharming Intellectual Property B V Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365478A (zh) * 2005-12-21 2009-02-11 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C1-inhibitor protects against brain ischemia–reperfusion injury via inhibition of cell recruitment and inflammation;Claudio Storini et al.;《Neurobiology of Disease》;20050221(第19期);第10-17页 *
Claudio Storini et al..C1-inhibitor protects against brain ischemia–reperfusion injury via inhibition of cell recruitment and inflammation.《Neurobiology of Disease》.2005,(第19期),第10-17页. *
Protective effect of C1 esterase inhibitor on acute traumatic spinal cord injury in the rat;R. Tei et al.;《Neurological Research》;20080930;第30卷;第761-767页 *

Also Published As

Publication number Publication date
DK2793935T3 (en) 2016-09-05
EP2793935A1 (en) 2014-10-29
CA2858984C (en) 2021-01-05
JP6127063B2 (ja) 2017-05-10
US9452203B2 (en) 2016-09-27
WO2013093027A1 (en) 2013-06-27
KR20140107567A (ko) 2014-09-04
KR102022231B1 (ko) 2019-09-19
AU2012318275B2 (en) 2016-05-19
EP2793935B1 (en) 2016-05-25
US20140371425A1 (en) 2014-12-18
ES2587863T3 (es) 2016-10-27
JP2015502389A (ja) 2015-01-22
AU2012318275A1 (en) 2013-07-11
CN104080474A (zh) 2014-10-01
HK1201729A1 (zh) 2015-09-11
CA2858984A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CN104080474B (zh) C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
ES2392596T3 (es) Neurregulina en el tratamiento de enfermedades cardiacas
Yao et al. MG53 permeates through blood-brain barrier to protect ischemic brain injury
ES2804424T3 (es) Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
Essien et al. Physiologic features of brain death
Salman et al. Acute hyperglycemia exacerbates hemorrhagic transformation after embolic stroke and reperfusion with tPA: a possible role of TXNIP-NLRP3 inflammasome
Sang et al. Early increased bradykinin 1 receptor contributes to hemorrhagic transformation after ischemic stroke in type 1 diabetic rats
US10772827B2 (en) Composition for treating apoplexy through nasal administration
Yuan et al. Inactivation of ERK1/2 signaling mediates dysfunction of basal meningeal lymphatic vessels in experimental subdural hematoma
US20080260644A1 (en) Chloride transport upregulation for the treatment of traumatic brain injury
Simats et al. Ceruletide and alpha-1 antitrypsin as a novel combination therapy for ischemic stroke
US20230108970A1 (en) Methods and compositions for improving kidney function in patients with hepatorenal syndrome
US20180207246A1 (en) Compositions and methods for treating post-operative complications of cardiopulmonary surgery
JP6535036B2 (ja) 出血性疾患の治療における止血を改善するためのヒトプロトロンビン及び活性化第ｘ因子の組成物
WO2012006585A2 (en) Use of interleukin-15 to treat cardiovascular diseases
US9974831B2 (en) Methods of reducing myocardial injury following myocardial infarction
US20200390872A1 (en) Treatment and prevention of pre-eclampsia
US10441631B2 (en) Therapeutic agent for amniotic fluid embolism
Elkhrbash The role of angiotensin AT1 and AT2 receptors in the development of apoptosis and inflammation following experimental myocardial infarction
Hernaningsih et al. Sindroma Cushing Pada Kehamilan
Ranasinghe et al. An unusual presentation of idiopathic thrombocytopenic purpura in pregnancy
JP2007262027A (ja) Ａｔ−ｉｉｉによる内因性ｉｇｆ−１の産生誘導剤
CN114470196A (zh) CCL3/CCR4中和抗体、NF-κB抑制剂在制备NEC治疗药物中的用途
Grbavac et al. Prevention and Treatment of Ovarian Hyperstimulation Syndrome
Abbara Physiological Roles of the Peptide Prokineticin 1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant